Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06611163 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06611163 · ClinicalTrials.gov record · last posted 2026-03-25

A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.

StatusActive, Not Recruiting
PhasePhase 3
Started2025-03-21
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis.

Amendment record 8 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 8 times since 2024-09-23; most recent amendment 2026-03-20. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-10-17
Status change Recruiting→Active, Not Recruitingv6
2025-05-19
Status change Not Yet Recruiting→Recruitingv3
Trial Details
NCT Number NCT06611163
Lead Sponsor Sun Pharmaceutical Industries Limited
Conditions Moderate to Severe Genital Psoriasis
Enrollment 206 participants
Start Date 2025-03-21
Primary Completion 2026-01-21 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-03-25